ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin?s lymphoma (iNHL) - CHRONOS-4
EudraCT number 2015-001088-38
Protocol number BAY80-6946/17833
Sponsor Bayer HealthCare, AG, Kaiser-Wilhelm-Allee 10, 51368 Leverkusen, Germany
Indications Oncology
Diagnosis indolent non-Hodgkin?s lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2015
Date of approval by Institute (SÚKL) 28.12.2015
Date of approval by EC 4.11.2015
Date of initiation CT in ČR 31.10.2017
Date of ending CT in ČR
Sites Fakultní nemocnice Královské Vinohrady, Interní hematologická klinika, Šrobárova 1150/50, 100 34 Praha 10

‹‹ Back to list